Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 11/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 9/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | BRD4 | O60885 | 1/20 | 0.81 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | EGFR | P00533 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | LTA4H | P09960 | 1/20 | 0.81 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vorinostat SCHEMBL9018 | 0.90 | HDAC1 (1.00) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL23055010 | 0.90 | HDAC1 (1.00) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL19754407 | 0.90 | HDAC1 (1.00) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL8261596 | 0.90 | HDAC1 (1.00) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL23055007 | 0.88 | HDAC1 (0.96) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL31635263 | 0.88 | HDAC1 (0.83) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL30535798 | 0.87 | HDAC6 (0.87) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL6386310 | 0.86 | HDAC6 (1.00) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL8587363 | 0.86 | HDAC1 (0.75) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL11694913 | 0.86 | HDAC8 (0.75) | HDAC1HDAC2HDAC6HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-8653278-B2 | Isoform selective HDAC inhibitors | GEORGETOWN UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653278-B2 | Isoform selective HDAC inhibitors | GEORGETOWN UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | GEORGETOWN UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | GEORGETOWN UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-2083005-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008019025-A2 | ISOFORM-SELECTIVE HDAC INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | HDAC1 1/4885HDAC2 4/4885HDAC6 11/4885 |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC2 10/4885HDAC6 11/4885 |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | HDAC1 1/4885HDAC2 6/4885HDAC6 22/4885 |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC2 8/4885HDAC6 11/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | HDAC1 5/4885HDAC2 31/4885HDAC6 557/4885 |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | HDAC5, HDAC6, HDAC3 | HDAC1 4/4885HDAC2 8/4885HDAC6 2/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | HDAC1 9/4885HDAC2 51/4885HDAC6 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.